109808 ⎘
dsDNA viruses; Details; Herpesviridae; Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY
#2COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST EPSTEIN-BARR VIRUS
#3EPSTEIN-BARR VIRUS VACCINES
#4Antigenic Epstein Barr Virus Polypeptides
#5DUAL FUNCTION ANTIGEN BINDING MOLECULES
#6PREFUSION STABILIZED EBV GB MUTATIONS AND USES THEREOF
#7Novel Epstein Barr Virus Immunotherapies
#8EPSTEIN-BARR VIRUS VACCINES
#9Multivalent Epstein-Barr virus-like particles and uses thereof
#10Anti-Abeta Therapeutic Vaccines
#11SELF-ASSEMBLED NANOPARTICLE CONTAINING gHgL PROTEIN OF EB VIRUS, PREPARATION METHOD AND USE THEREOF
#12VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#13Ferritin Proteins
#14MODULATED IMMUNODOMINANCE THERAPY
#15Epstein-Barr Virus antigen constructs
#16EBV-TARGETED ALLOGENEIC B CELL VACCINE AND PREPARATION METHOD THEREFOR
#17METHOD FOR MANUFACTURING HEK293 CELL LINE, METHOD FOR MANUFACTURING EB-VLPs AND COMPOSITION COMPRISING SAID EB-VLPs
#18Antigen presenting scaffolds for immune-cell manipulation
#19MEANS AND METHODS FOR TREATING HERPESVIRUS INFECTION
#20MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY
#21METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES
#22BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
#23POLYPEPTIDES FOR TREATMENT OF AML
#24Pepmixes to generate multiviral CTLS with broad specificity
#25Pepmixes to generate multiviral CTLs with broad specificity
#26Human herpesvirus immunotherapy
#27MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY
#28Epstein-barr virus antigen constructs
#29Means and methods for treating herpesvirus infection
#30VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
#31VACCINE COMPOSITION
#32Ferritin proteins
#33Anti-abeta therapeutic vaccines
#34Self-asssembling nanostructure vaccines
#35Epstein-barr virus vaccines
#36EPSTEIN-BARR VIRUS VACCINES
#37Multivalent Epstein-Barr virus-like particles and uses thereof
#38Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
#39METHOD FOR TREATING EPSTEIN-BARR VIRUS - POSITIVE CANCER WITH IMMUNOTHERAPY
#40Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
#41Viral vector constructs for expression of genetic adjuvants activating the STING pathway
#42Antigen presenting scaffolds for immune-cell manipulation
#43Anti-abeta therapeutic vaccines
#44EBV vaccine
#45Amino acid and peptide conjugates and uses thereof
#46Vaccine composition
#47Vaccine composition
#48MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
#49Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
#50Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
#51Immunogenic construct comprising an EBV-cell antigen and a targeting moiety and applications thereof
#52Anti-BARF1 monoclonal antibody
#53B-cell receptor complex binding proteins containing T-cell epitopes
#54Multimeric fusion protein vaccine and immunotherapeutic
#55Human herpesvirus immunotherapy
#56Pepmixes to generate multiviral CTLs with broad specificity
#57Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
#58Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereof
#59Amino acid and peptide conjugates and uses thereof
#60Method for treating epstein-barr virus—positive cancer with immunotherapy
#61METHOD FOR INDUCING T CELLS FOR CELL-BASED IMMUNOTHERAPY
#62Modulated immunodominance therapy
#63Antigenic epitopes from EBV gp350/220 and uses thereof
#64Method for priming of T cells
#65MODULATED IMMUNODOMINANCE THERAPY
#66MODULATED IMMUNODOMINANCE THERAPY
#67Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
#68Epstein-Barr virus vaccines
#69Epstein-Barr-virus vaccine
#70T cell receptors
#71Vaccine composition
#72MULTI-EPITOPIC VACCINE
#73Human herpesvirus immunotherapy
#74Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
#75BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
#76Multimeric fusion protein vaccine and immunotherapeutic
#77Modular nanodevices for smart adaptable vaccines
#78B-cell receptor complex binding proteins containing T-cell epitopes
#79Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes
#80Method for priming of T cells
#81NON-SPLICING VARIANTS OF GP350/220
#82Recombinant vaccines
#83Multi-epitopic vaccine
#84NON-SPLICING VARIANTS OF gp350/220
#85CONSTRUCT SYSTEM AND USES THEREFOR
#86Pharmaceutical composition comprising an antigen
#87Expression system for modulating an immune response
#88Therapeutic calcium phosphate particles and methods of manufacture and use
#89NON-SPLICING VARIANTS OF GP350/220
#90Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
#91Use of Urea-Adjuvated Polypeptides for Diagnosis, Prophylaxis and Therapy
#92Expression system for modulating an immune response
#93FUSION MULTIVIRAL CHIMERIC ANTIGEN
#94Non-Splicing Variants of gp350/220
#95TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES
#96Direct vaccination of the bone marrow
#97Pharmaceutical Composition Comprising An Antigen
#98Recombinant flavivirus vaccines
#99NOVEL VACCINATION
#100Therapeutic calcium phosphate particles and methods of manufacture and use
#101Non-splicing variants of gp350/220
#102VIRAL GENE PRODUCTS AND METHODS FOR VACCINATION TO PREVENT VIRAL ASSOCIATED DISEASES
#103Assays and therapies for latent viral infection
#104Assays and therapies for latent viral infection
#105Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment
#106Pharmaceutical composition comprising an antigen
#107Assays and therapies for latent viral infection
#108Novel vaccination